Before joining Triumvira, Ms. Molina was most recently VP of Global Regulatory Affairs at Cell Medica, Inc in Houston, TX, for 6 years and accumulated 30 years of experience in multiple facets of product development for pharmaceutical, biotechnology, biologic, and in vitro diagnostic products, with a primary focus on regulatory affairs. In addition to regulatory affairs, her experience includes clinical and preclinical strategic planning, quality assurance, process development and manufacturing for oncology and infectious disease products.
Ms. Molina has experience leading preparation of a variety of global regulatory submissions, including INDs, NDAs, BLAs, MAAs, global CTAs, 510Ks, PMAs, orphan and Fast Track submissions, and clinical study reports. She has held management positions at both large and small corporations, including Abbott Laboratories.
Joshua Carle, MBA, is a cross-functional executive with 20 years of strategic transaction and R&D investment experience while in Management Consulting and BioPharma. Mr. Carle has led or advised more than fifty potential strategic transactions, resulting in the successful execution of greater than $2 billion in disclosed deal value and committed R&D funds. Mr. Carle joins from Pfizer Inc., where he drove BD strategy, commercial assessments, and broad transaction support for licensing/M&A efforts for Pfizer Oncology.
Previously, Mr. Carle held roles of increasing responsibility in business development activities at Daiichi Sankyo Inc. and Clearview Projects Inc., a strategic advisory firm focused on licensing/M&A for the BioPharma industry. Mr. Carle received his undergraduate degree in Economics from the University of Pennsylvania and MBA from the Villanova School of Business.
Mr. Jon Irvin joined Triumvira as the Vice President of Finance in January 2018. Prior to Triumvira, Mr. Irvin was the Chief Financial Officer and Vice President of Finance at Mirna Therapeutics. He also served as the Chief Executive Officer and Vice President of Finance for Voxpath Networks, Inc., a telecommunications and intellectual property company. Previously, Mr. Irvin was in executive financial positions at Reddwerks Corporation, a software company, Esoterix, Inc., a medical laboratory company, Topaz Technologies, a pharmaceutical software company, and BioNumerik Pharmaceuticals, Inc., a pharmaceutical company. Mr. Irvin began his career as an accountant with Price Waterhouse (senior) and Ernst & Young (senior manager). He received a B.S. in Accounting from the University of Illinois, and his Certified Public Accountant designation in California.
Ms. McRoberts brings more than four decades of experience in the financial sector across both the buy-side and sell-side with a focus on healthcare. Prior to joining Triumvira, she was Portfolio Manager, Senior Vice President, and Senior Analyst at Alger Management, a growth-style investment management company, where she grew Alger’s Health Sciences Trust into a top 10% healthcare mutual fund. She was also previously Portfolio Manager at Morgan Stanley, Portfolio Co-Manager at Tribeca Global Management, a hedge fund owned by Citigroup, and an analyst and investment banker with J.P. Morgan. Ms. McRoberts holds a Master of Business Administration from Columbia Business School and a Bachelor of Arts in English from Oberlin College.
Dr. Andreas Bader joined Triumvira in 2018. Dr. Bader is a seasoned biotech executive with more than 20 years of experience in oncology drug discovery and development, and business and research strategies. Previously, Dr. Bader acted as Co-Founder and CEO of Orros Biotherapeutics LLC, and as a scientific Co-Founder of Mirna Therapeutics, Inc., where he held multiple leading positions in R&D and led research programs from discovery to the completion of Phase 1 clinical trial. Prior to Mirna, Dr. Bader functioned as the Scientific Lead of the microRNA therapeutics program at Asuragen, Inc. Dr. Bader completed his post-doctoral training at The Scripps Research Institute, La Jolla, California, received his PhD in Biochemistry and his MSc degree in Biology from the University of Innsbruck, Austria.
Ms. Rill joined Triumvira as Chief Technology Officer in June 2018. Prior to Triumvira, Ms. Rill, an accomplished expert in cellular therapy manufacturing, was responsible for the design and qualification of cell & gene therapy laboratories using novel technologies, cGMP vector production facilities, core service laboratories, and translational research laboratories. In addition to her construction, project management and regulatory/QA/QC/(c)GxP knowledge, she brings extensive operational and strategic experience in cell and gene therapy, monoclonal antibody production, and protein production. Ms. Rill will oversee all North American operations for Triumvira.
Ms. Rill’s earlier positions include Vice President of Manufacturing for Cell Medica, Chief Development Officer for Opexa Therapeutics, Laboratory Director of Cell and Gene Therapy at Baylor College of Medicine (Head: Prof. Malcolm Brenner); and Lab Manager of the GMP Cell & Gene Therapy Laboratories at St. Jude Children’s Research Hospital.
Dr. Adib brings to Triumvira Immunologics over 24 years of medical oncology experience in the biotech and pharmaceutical industries, including 7 successful registrations across various hematologic as well as solid tumor maladies. Most recently, he was the founder of MariCel Clinical Consulting , LLC. Offering strategic services to the biotech industry.
Dr. Adib held multiple seats as a scientific advisory board member at several biotech companies including Imbrium therapeutics a Perdue Pharma subsidiary and a strategic consultant for advanced cell therapy programs through 1st IND at Bellicum pharmaceuticals for the BPX-601: GoCAR-T® currently in Phase I/II clinical trials for solid tumors and at KSQ for eTIL™ autologous cell therapy candidates, KSQ-001.
Past leadership roles include acting Chief Medical Officer at Rain Therapeutics advancing the clinical programs and designing clinical strategy to build the oncology portfolio leading to a successful IPO. In addition, Dr. Adib was Vice president late-stage development at Blueprint Medicines and global therapeutics Head for Solid Tumors at Baxalta, Inc., advancing the development of imalumab in various solid tumors and licensing a nano liposomal irinotecan later approved for pancreatic cancer & leading the clinical evaluation for acquiring Oncaspar from Sigma-Tau Pharmaceuticals (Leadiant Biosciences, Inc.) approved in ALL. He also led the licensing of a CD19 target CAR-T from Precision Biosciences and a PDL1, LAG3, TIM3 check point inhibitor targets from Symphogen a subsidiary of Servier. He was head of hematologic Malignancies at ARIAD leading the global clinical programs for ponatinib in CML later acquired by Takeda.
Dr. Adib has also held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma where he advanced the development of docetaxel in prostate cancer, breast cancer and gastric cancer, enzalutamide in prostate cancer, quizartinib in AML, erlotinib in NSCLC and pancreatic cancer.
Dr. Adib obtained his medical degree from Cairo University School of Medicine, Cairo, Egypt, and completed his postgraduate oncology training at the Anglo-American Hospital Association, Cairo, Egypt and Tufts University School of Medicine– Clinical Pharmacology, Drug Development and Regulation.
Robert F. Williamson, III has been active in building biotechnology companies and shareholder value for over two decades. He currently is President and CBO of Triumvira Immunologicals. Previously, he was the CBO of OncoMyx, an oncolytic virus company, and CEO of BioTheryX, a protein degradation therapeutics company, raising a $100M crossover round and preparing the company for an IPO. Prior to BioTheryX, Mr. Williamson served as CEO of both PharmAkea and ATXCo, oncology and fibrosis companies financed through a partnership with Celgene, until PharmAkea’s acquisition by Galecto and ATXCo’s acquisition by Blade Therapeutics. Prior, Mr. Williamson was CEO of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which he sold to Protein Design Labs, and COO of DoubleTwist, Inc. through its acquisition by Merck and Hitachi. Mr. Williamson also serves as a director and adviser for foundations, private, and public companies. Notably, Mr. Williamson served as an early Director of Pharmasset, Inc., where he helped finance, grow, and advance the company into the public markets and through its acquisition by Gilead in 2011 for $11 billion. Earlier, Mr. Williamson was a partner with The Boston Consulting Group and a research assistant for the Federal Reserve Board. He received a BA in economics from Pomona College and an MBA from Stanford.
Paul Lammers, MD, MSc, joined Triumvira Immunologics as President and CEO in January 2018. Before Triumvira, Dr. Lammers served as President & CEO at Mirna Therapeutics, for which company he raised $160 million through venture capital and Federal and State government funding, as well as a public listing on NASDAQ. Previously, he served as Chief Medical Officer and Head of US Product Development for EMD Serono.
During his early industry tenure, Dr. Lammers also held various executive/senior management positions in clinical development, medical and regulatory affairs, at different pharmaceutical companies, as well as at small public and privately held biotech companies. Dr. Lammers serves as Lead Independent Director for publicly-traded Salarius Pharmaceuticals, and as Director for a private biotech company, Immunomet.